Abstract Search

ea0047oc27 | Spotlight on Prostate Cancer | Theranostics2016

Initial experience with aggressive treatment of metastastic prostate cancer using 3 cycles of 7.4 GBq [177Lu]-PSMA every 4 weeks

Haug Alexander , Wadsak Wolfgang , Mitterhauser Markus , Shariat Shahrokh , Kramer Gero , Hacker Marcus , Hartenbach Markus

Aim: Given the aggressive biological features of metastatic prostate cancer, a more aggressive treatment with [177Lu]-PSMA might be appropriate.Materials and methods: We have treated 15 patients (mean age 69 years) with intended 3 cycles of [177Lu]-PSMA every 4 weeks. All patients have been examined with [68Ga]-PSMA PET/MRI to validate PSMA expression of all metastatic lesions. We monitored haemoglobin (Hb), platelets (Pl), leucocytes and creatinine for ...

0 shares

ea0052p36 | (1) | UKINETS2017

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

Nicolas Guillaume , Baum Richard , Herrmann Ken , Lassmann Michael , Hicks Rodney , Haug Alexander , Navalkissoor Shaunak , Oberwittler Heike , Wang Tiffany , Wild Damian

Introduction: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin receptor (SSTR) agonists is highly effective and has become an integral part of neuroendocrine tumour (NET) treatment. However, tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. OPS201 (DOTA-JR11) is a very promising next-generation SSTR antagonist selective for SSTR2 (expressed by NETs). This phase 1/2, international, single-...

0 shares

Endocrine Abstracts

Initial experience with aggressive treatment of metastastic prostate cancer using 3 cycles of 7.4 GBq [177Lu]-PSMA every 4 weeks

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

BiosciAbstracts

Endocrine Abstracts

Initial experience with aggressive treatment of metastastic prostate cancer using 3 cycles of 7.4 GBq [177Lu]-PSMA every 4 weeks

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

BiosciAbstracts

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours